The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large dataset.
S everal agents have been approved since 2011 for the treatment of unresectable or metastatic melanoma (MM). The first agent to demonstrate an improvement in overall survival (OS) in a randomized, controlled phase 3 trial was ipilimumab, which blocks the immune checkpoint molecule, cytotoxic T-lymphocyte antigen-4, to augment antitumor immunity.
1,2 Subsequent approved therapies target mutant (Mut) BRAF kinase, which occurs in approximately 50% of all melanomas, or MEK, the downstream target of BRAF. 3 The most common BRAF mutation is V600E, accounting for 70%-80% of BRAF mutations, with other mutations at the V600 position (eg, V600K) accounting for 5% to 15%. 3 The BRAF inhibitor, vemurafenib, was approved in 2011 for the treatment of BRAF V600E Mut MM based on an improvement in OS in a phase 3 trial. 4 In 2013, the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, were approved for BRAF V600E Mut and BRAF V600E/V600K Mut MM, respec tively, based on improvements in progression-free survival (PFS) in phase 3 trials. 5, 6 The combination of a BRAF inhibitor with a MEK inhibitor has demonstrated greater improvements in PFS and OS compared with a BRAF inhibitor alone in phase 3 trials of patients with BRAF V600 Mut MM. [7] [8] [9] Unlike the BRAF or MEK inhibitors, ipilimumab's mechanism of action is independent of the BRAF signaling pathway because it targets the immune system rather than tumor cells. 10 Tumors also exploit the immune checkpoint molecule, programmed death-1 (PD-1), to turn off the immune response by inactivating T cells at the tumor site.
11
Nivolumab is an anti-PD-1 monoclonal antibody that is believed to break down tumor defenses either by preventing inactivation or by reactivating T-cell activity within the tumor microenvironment. 11 In 2014, nivolumab was the first anti-PD-1 antibody to gain regulatory approval in Japan and was approved to treat patients with MM. 12 Pembrolizumab and nivolumab were subsequently approved in the United States for the treatment of MM following progression on ipilimumab or a BRAF inhibitor. 13, 14 To our knowledge, to date, there has not been any mechanistic evidence that BRAF mutations can have a direct impact on responses to immune checkpoint inhibitors. Retrospective analysis of data from an ipilimumab phase 2 study 15 and observational data from US medical record review 16 suggest that ipilimumab has similar activity in MM with wild-type (WT) BRAF kinase and Mut BRAF kinase. Evidence also exists that Mut BRAF does not substantially affect the antitumor activity of concurrent nivolumab and ipilimumab. 17 Initial data from the phase 3 CheckMate 037 18 study suggest that nivolumab as monotherapy is an effective treatment for patients with advanced melanoma independent of BRAF mutation status. In this study, the objective response rate was 23% among patients who had tumors with BRAF Mut kinase and was 34% among those with BRAF WT kinase. To provide a broader data set to answer the question as to whether nivolumab activity is independent of BRAF Mut status in patients with advanced melanoma, we conducted a retrospective pooled analysis in nivolumab-treated patients with BRAF V600 Mut or WT tumors.
Methods

Patients
Ongoing studies in which patients had received nivolumab monotherapy for unresectable stage III or stage IV melanoma following prior systemic therapy for advanced disease, and which enrolled patients with tumors unselected for BRAF mutational status, were included in the current data set (eTable 1 in the Supplement positive if at least 5% of tumor cells had cell-surface PD-L1 staining of any intensity in a section containing at least 100 evaluable tumor cells.
Statistical Analysis
Objective response rates with 95% CIs were estimated using the Clopper-Pearson method. Medians for duration of objective response were calculated using the Kaplan-Meier method, with 95% CIs based on the Greenwood formula. Duration of response was defined as the time between the date of first documented objective response and the date of the first subsequent disease progression or death due to any cause, whichever occurred first. For patients whose disease progressed or who died, the duration of objective response was censored at the same time that they were censored for the primary definition of PFS.
Results
A total of 440 nivolumab-treated patients from 4 clinical studies met the criteria for inclusion in the current analysis: 334 patients with BRAF WT tumors and 106 patients with BRAF V600 Mut tumors. Baseline characteristics of all patients included in the analysis are shown in Table 1 . Patient characteristics were well balanced between the WT and Mut BRAF 
Objective Response
Among 291 patients evaluated for response, the percentage with a complete or partial response was similar in the WT BRAF and Mut BRAF groups ( Table 2 ). The objective response rate was 34.6% for the WT BRAF group (75 responses among 217 patients) and was 29.7% for the Mut BRAF group (22 responses among 74 patients) ( Table 2 ). The median time to objective response was 2.2 months in both groups. The median duration of objective response was similar in the WT BRAF group (14.8 months; 95% CI, 11.1-24.0) and the Mut BRAF group (11.1 months; 95% CI, 7.3-22.9) ( Table 2) . Similar percentage reductions in the magnitude of tumor burden were observed between WT BRAF ( Figure 1A) and Mut BRAF ( Figure 1B ). Objective response rates with nivolumab treatment were not markedly different between WT and Mut BRAF across subgroups, including those defined by baseline lactate dehydrogenase levels, metastasis stage, or PD-L1 status ( Figure 1C) . Figure 2 depicts the time to first response and duration of response in both groups; 59 of 75 WT BRAF patients (78%) and 16 of 22 Mut BRAF patients (73%) remained in response. Among patients who discontinued treatment and remained in response, the median duration of response was 4.8 months for WT BRAF (n = 13 patients) and was 5.0 months for Mut BRAF (n = 2 patients).
Prior BRAF Inhibitor Therapy An exploratory analysis was performed to assess whether prior BRAF inhibitor therapy in Mut BRAF patients had an impact on response to nivolumab. The objective response rate was 33.1% in Mut BRAF patients with no prior BRAF inhibitor therapy and was 24.5% in patients who had received a prior BRAF inhibitor (eTable 2 in the Supplement). Reductions in the magnitude of tumor burden in Mut BRAF patients were similar regardless of prior BRAF inhibitor therapy (eFigure 1 in the Supplement).
Safety
In the safety analysis, which included all patients, the overall incidence of treatment-related adverse events was similar in WT BRAF (and Mut BRAF groups ( Table 3 ) (68.3% and 58.5% patients, respectively). Grade 3 or 4 adverse events occurred in 11.7% of WT BRAF patients and in 2.8% of Mut BRAF patients. The most common treatment-related adverse eventss of any grade (occurring in ≥10% of patients) were fatigue, pruritus, rash, and diarrhea. The rates of treatment-related select adverse eventss were similar between groups and were comparable with those in the total population: 46.1% of any grade for WT BRAF, 34% for Mut BRAF, and 43.2% for the total population; the rate of grade 3 or 4 adverse eventss was 3.6% in the WT BRAF group, 0% in the Mut BRAF group, and 2.7% in the total population (eTable 3 in the Supplement). Among the Mut BRAF patients, grade 3 or 4 adverse eventss occurred in 37% of patients who had received a prior BRAF inhibitor (n = 76) compared with 30% of patients who had not received a prior BRAF inhibitor (n = 30).
Discussion
The results of this retrospective analysis of pooled data from 4 clinical studies suggest that nivolumab has clinical activity with a manageable safety profile in patients with advanced melanoma, regardless of BRAF mutational status. The objective response rate, time to response, and duration of response seemed similar in patients with WT or Mut BRAF who received nivolumab. Our findings are consistent with the results of a recent study with the anti-PD-1 antibody, pembrolizumab, in which the objective response rate was 28% in 131 patients with WT BRAF MM and was 19% in 26 patients with gest a consistent objective response rate between both groups of patients. There were no substantial differences in subgroups defined by lactate dehydrogenase levels, M stage, PD-L1 status, or prior therapy with ipilimumab or a BRAF inhibitor. Although the patients had been heavily pretreated prior to nivolumab, many were still able to respond to the drug in both groups.
The current findings are consistent with the results of a recent phase 3 trial in previously untreated patients with WT BRAF, in which nivolumab at 3 mg/kg every 2 weeks produced an objective response rate of 40.0%. 25 Because the current analysis was conducted on a data set from previously treated patients, we evaluated the impact of prior BRAF inhibitor therapy on the response to nivolumab. In Mut BRAF patients, the objective response rates were similar between the cohort that received a prior BRAF inhibitor and the cohort that had not received a prior BRAF inhibitor. There were no new safety signals in patients who received a BRAF inhibitor prior to nivolumab, and the incidence of grade 3 or 4 adverse events did not seem to be markedly affected by prior BRAF inhibitor therapy.
The retrospective nature of this nonrandomized cohort analysis, with subgroups having small numbers of patients, is an important limitation of the analysis. We evaluated patients with MM harboring the BRAF V600E mutation, but the potential impact of other BRAF or MAPK variants on efficacy and safety outcomes with nivolumab cannot be ruled out. It is also important to note that the current data set includes patients who were eligible to receive additional treatment, particularly the Mut BRAF patients who had prior BRAF inhibitor therapy. Thus, the patients in this analysis may have had a better prognosis than other Mut BRAF patients who may be too ill to be treated further. Survival follow-up of the patients may be presented in the future when data become more mature.
The current data suggest that some patients with Mut BRAF who receive BRAF inhibitor therapy will respond to subsequent immunotherapy with nivolumab. These findings may have implications for the sequencing of BRAF/MEK inhibitors with immune checkpoint inhibitors. Some treatment guidelines for advanced melanoma recommend the use of a BRAF inhibitor as the initial treatment of patients with BRAF Mut disease who have a poor performance status. 26 However, the results of retrospective analyses suggest that better outcomes occur when ipilimumab is used prior to a BRAF inhibitor compared with the reverse treatment sequence. 27, 28 The results of the current analysis suggest that nivolumab has activity regardless of prior BRAF inhibitor or ipilimumab treatment, although the small numbers of patients limit the ability to make definitive conclusions on whether prior BRAF inhibitor therapy has a negative impact on the response to nivolumab. Further prospective studies will be required to determine the optimal treatment schedule for BRAF/MEK inhibitors and immune checkpoint inhibitors in advanced melanoma.
Conclusions
This pooled analysis represents the largest data set available to date to evaluate the efficacy and safety of nivolumab in WT and Mut BRAF patients with MM. Within the limitations of this retrospective analysis, the data suggest that nivolumab has activity in patients with WT BRAF and in patients with Mut BRAF, consistent with findings of previous retrospective analyses of ipilimumab monotherapy 15 and a phase 1 study of concurrent nivolumab and ipilimumab. 17 Moreover, nivolumab monotherapy may be an effective treatment for Mut BRAF patients regardless of whether they have previously received a BRAF inhibitor. 
